Home iSTAR Medical SA

iSTAR Medical SA

    iSTAR Medical MINIject

    Company reports The STAR-I trial demonstrated that the implantation of MINIject resulted in a mean pressure of 15.0mmHgat 18-months, consistent with results reported at 1 year, and at a level expected to reduce the progression of glaucoma.

    iSTAR Medical’s MINIject Maintains Exceptional Results in First-in-Human Trial One Year Post-Surgery ( STAR- I)

    12/19/18: STAR-I trial demonstrated that the implantation of MINIject resulted in an average 32.6% IOP reduction to a mean of 15.6 mmHg at one year.

    iSTAR Medical Reports MINIject Delivers Exceptional 6-Month Results in First-in-Human Trial

    5/16/18: The results show MINIject to be safe and highly effective in achieving significant intraocular pressure (IOP) reduction in glaucoma patients.

    RECENT COMMENTS